Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
CurveBeam AI (ASX:CVB), a medical imaging device company, has had a frustrating period, according to Firetrail Investments. In December 2024, Firetrail noted CurveBeam had a frustrating 12 months, with sales of its HiRise weight-bearing CT device stalled as it worked with key distribution partners to improve market access. CurveBeam AI operates in the Healthcare sector within the Healthcare Equipment and Supplies industry, and Thesis Tracker has captured 1 comment from 1 fund manager, Firetrail Investments. Founded in 2022 and headquartered in Melbourne, CurveBeam AI designs and manufactures weight-bearing cone beam CT imaging systems for orthopaedics, including the HiRise and LineUP devices, which allow clinicians to image the foot, ankle, knee and hand while the patient is standing, supported by AI-driven analysis software, and sells primarily in the United States through distributors and direct sales, targeting orthopaedic clinics and hospitals.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Firetrail Investments have invested in Curvebeam AI Ltd (ASX:CVB).
The available commentary does not highlight specific opportunities, though CurveBeam's weight-bearing CT technology offers a differentiated approach to orthopaedic imaging.
Firetrail highlights stalled HiRise sales as CurveBeam worked through distribution partner issues, leading to a frustrating year for investors.
CurveBeam AI Ltd. is an Australian medical technology company headquartered in Melbourne. Founded in 2022, the company specializes in the research, design, and manufacture of cone beam computed tomography (CBCT) imaging systems. CurveBeam AI operates globally, with business activities segmented into North America, Europe, and the Rest of World. The company provides advanced diagnostic imaging solutions for clinical applications.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.